We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

MRC Technology and Proximagen Collaborate


Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "MRC Technology and Proximagen Collaborate"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
 

MRC Technology and Proximagen Group Limited have entered into collaboration to progress small molecules for the treatment of inflammatory and autoimmune disease.  Proximagen is a UK-based biotechnology company focused on the development and commercialisation of novel therapeutics for diseases of the central nervous system (CNS) and is owned by Upsher-Smith Laboratories, Inc., a Minnesota-based growing pharmaceutical company.

Applying MRC Technology’s medicinal chemistry expertise, the project will focus on the potential of the enzymatic cytokine, Macrophage migration inhibitory factor (MIF), as a key target and progress the research towards proof of concept in an animal model with future commercialisation potential. 

MIF is a multipotent cytokine that has been implicated in the pathogenesis of numerous autoimmune inflammatory disorders. MRC Technology will investigate the therapeutic potential of the MIF inhibitors through proof of concept studies in animal models including efficacy, pharmacokinetic and toxicology data. This work will be carried out as a prelude to MRC Technology identifying commercial partnering opportunities for the project and subsequent progression towards the clinic.

Michael Dalrymple, Director of Business Development at MRC Technology commented: “This collaboration represents a new shared-risk model for us to meet our objective of pushing new healthcare discoveries towards the market, by working with companies to help progress their promising but less-prioritised projects. We are hopeful that this collaboration will lead to compounds with proof of efficacy ready for partnering with industry.”

“The selective inhibition of MIF has the potential to offer new therapeutic avenues for inflammatory and autoimmune disease,” commented Martyn Pritchard Ph.D, Head of R&D at Proximagen. “We are delighted to be working with MRC Technology and their expert team to further progress this important project.”

Advertisement